Pharmather Holdings advances KETARx after FDA approval

Executive Summary

• Pharmather Holdings is advancing its ketamine transdermal patch as a next-generation, non-opioid pain relief solution, leveraging the recent FDA approval of its IV ketamine product, KETARx.
• The company aims to address the unmet medical need for non-opioid alternatives in a U.S. pain management market valued at over $50 billion annually.
• Pharmather intends to pursue the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program for the patch, which could allow for ultra-accelerated New Drug Application (NDA) review timelines of one to two months.

Key Details

• Product Development: The ketamine patch is designed to deliver controlled, sustained analgesia for acute postoperative pain and chronic pain conditions, suitable for hospital, outpatient, and home-care settings.
• Regulatory Strategy: The company plans to utilize the 505(b)(2) regulatory pathway for additional indications and the CNPV pilot program to accelerate NDA review for the patch.
• Market Context: The U.S. pain management market is valued at over $50 billion, with acute postoperative pain representing a $13 billion opportunity and chronic pain exceeding $30 billion.
• Strategic Synergy: The strategy combines the proven clinical and regulatory foundation of the approved IV ketamine (KETARx) with the novel transdermal delivery system to expand ketamine’s role into new care settings.
• Future Opportunities: Beyond pain management, Pharmather may explore the patch for mental health conditions, including treatment-resistant depression, suicidality, and PTSD.

Notable Quotes

• "With KETARx now FDA-approved, our next chapter is to expand ketamine's impact through an innovative transdermal patch that can redefine pain management," said Fabio Chianelli, founder and chief executive officer of Pharmather.